Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology Virtual Meeting Experience (AAD VMX), held virtually from April 23-25, 2021.
Presentations at AAD VMX will feature new findings on disease control and quality-of-life measures from the Phase 3 TRuE-AD clinical trial program evaluating the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis (AD). Additionally, 104-week data from the Phase 2 study of ruxolitinib cream in patients with vitiligo will be featured, along with findings about the maintenance of repigmentation following treatment.
“We look forward to the opportunity to showcase additional data from our Phase 2 and Phase 3 studies of ruxolitinib cream, which provide further insights on the potential of this investigational therapy to become an important treatment option for patients living with AD and vitiligo,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “Chronic skin conditions like AD and vitiligo can be life-altering and have serious impacts, and we hope this research will advance the overall understanding of the needs of people living with these conditions as we seek to provide therapies that can offer meaningful improvements.”
Key abstracts from Incyte-sponsored studies include:
e-Posters with Oral Presentation
Vitiligo (Category: Pigmentary Disorders & Vitiligo)
Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data from a Phase 2 Study (Abstract #27535)
Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients with Vitiligo (Abstract #27568)
Atopic Dermatitis (Category: Dermatitis, Atopic)
Efficacy and Safety of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #27633)
Effects of Ruxolitinib Cream in Patients with Atopic Dermatitis with Baseline Body Surface Area ≥10% and Eczema Area and Severity Index Score ≥16: Pooled Results from Two Phase 3 Studies (Abstract #27620)
Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis from Two Randomized Phase 3 Studies (Abstract #27716)
Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Patient Demographics: Pooled Subgroup Analysis from Two Randomized Phase 3 Studies (Abstract #27496)